Navigation Links
NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow
Date:5/13/2013

Milford, Massachusetts (PRWEB) May 13, 2013

NITTO DENKO Avecia Inc., an industry leader in therapeutic nucleic acid manufacturing and development services, is proud to introduce a new pre-clinical oligonucleotide synthesis service, OliGrow. Combining phase appropriate quality and purity standards with a high level of customer service, the Avecia OliGrow team delivers pre-clinical oligonucleotides at µmol to mmol scales, with affordable pricing and fast turn around times.

OliGrow offers custom DNA and RNA with standard chemical modifications, along with advanced solutions for more specialized needs, including oligonucleotide conjugates and specialty amidites. Its experts operate within a dedicated facility at Avecia’s FDA- registered Cincinnati, OH plant, and use instrumentation, methods, and analytics designed for scalability and consistency throughout the development process.

As the only oligonucleotide CMO that can deliver both the first µmols of pre-clinical material and bring a program through to commercialization, Avecia OliGrow creates value for its customers by building compound knowledge from the very start, avoiding future surprises and costly technical transfers and process changes.

Dr. Marc Lemaitre, Avecia’s VP for New Businesses and Services, says the company is very proud to bring this small scale service under the same roof as the large scale, clinical productions. “Previous options to bridge the gap between pure research and clinical production in the oligo space were largely accomplished through collaborations and partnerships between multiple companies. But now are pleased to offer OliGrow as a unique, one- stop option for oligonucleotide developers.”

ABOUT NITTO DENKO Avecia Inc.

NITTO DENKO Avecia, Inc. is a drug development and manufacturing services company located in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader process development, manufacture, and related services for DNA and RNA-based therapeutics. All services are offered, from preclinical testing to post-commercial launch of innovative oligonucleotide-based therapeutics. To see what Avecia can do for your business, visit http://www.avecia.com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10715509.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
2. Montclair Breast Center introduces 3D Mammography.
3. Adult Acne Treatment, Probiotic Action Introduces their Antibiotic-Free Acne Treatment
4. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
5. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
6. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
7. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
8. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
9. Rigaku Introduces New Instruments at Pittcon 2013
10. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
11. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... MONTREAL , Jan. 24, 2017 /PRNewswire/ - BioAmber Inc. ... demand, the underwriters have agreed to increase the size of ... stock of the Company, together with warrants to purchase 1,842,106 ... price of US$5.50 per share of common stock (the "Exercise ... share and associated warrant (the "Public Price"). The warrants have ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... label-free graphene biosensor assays for fragment-based screening, will showcase its proprietary ... Society for Laboratory Automation and Screening (SLAS) conference in Washington, D.C. from Feb. ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences ... announced today that its orally active lead drug candidate, ... designation by the UK Medicines and Healthcare Products Regulatory ... A PIM designation is an early ... for the Early Access to Medicines Scheme ("EAMS"), intended ...
(Date:1/24/2017)... ... January 23, 2017 , ... Oklahoma City based Sigma Blood ... for the firm’s PERFEQTA software and legacy product QC Manager 2.0. , Sigma ... team at CJBC and thrilled that they have decided to implement PERFEQTA and QC ...
Breaking Biology Technology:
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
Breaking Biology News(10 mins):